Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
On July 31, 2023, NeoGenomics’ competitor, Natera, Inc., announced that it had sued NeoGenomics in federal court, alleging that the Company’s cancer test, the RaDaR molecular residual disease assay, infringed Natera’s patents.
On December 27, 2023, Natera announced that the federal court had issued a preliminary injunction, effective immediately, barring NeoGenomics from making, using, selling, or promoting the RaDaR test, but that NeoGenomics may continue to offer RaDaR to existing patients and for clinical trials, studies, or projects already in process.
The following day, NeoGenomics acknowledged the preliminary injunction, announcing that it would appeal the federal court’s ruling.
On this news, NeoGenomics’ stock price fell $3.71 per share, or 18.1%, to close at $16.79 per share on December 28, 2023.